ID   TAOK1_HUMAN             Reviewed;        1001 AA.
AC   Q7L7X3; A2RUT8; B7ZLV6; Q96L75; Q9H2K7; Q9H7S5; Q9P2I6;
DT   25-OCT-2005, integrated into UniProtKB/Swiss-Prot.
DT   05-JUL-2004, sequence version 1.
DT   12-OCT-2022, entry version 170.
DE   RecName: Full=Serine/threonine-protein kinase TAO1;
DE            EC=2.7.11.1;
DE   AltName: Full=Kinase from chicken homolog B;
DE            Short=hKFC-B;
DE   AltName: Full=MARK Kinase;
DE            Short=MARKK;
DE   AltName: Full=Prostate-derived sterile 20-like kinase 2;
DE            Short=PSK-2;
DE            Short=PSK2;
DE            Short=Prostate-derived STE20-like kinase 2;
DE   AltName: Full=Thousand and one amino acid protein kinase 1;
DE            Short=TAOK1;
DE            Short=hTAOK1;
GN   Name=TAOK1; Synonyms=KIAA1361, MAP3K16, MARKK;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, TISSUE SPECIFICITY, AND
RP   SUBCELLULAR LOCATION.
RX   PubMed=13679851; DOI=10.1038/sj.onc.1206605;
RA   Yustein J.T., Xia L., Kahlenburg J.M., Robinson D., Templeton D.,
RA   Kung H.-J.;
RT   "Comparative studies of a new subfamily of human Ste20-like kinases:
RT   homodimerization, subcellular localization, and selective activation of
RT   MKK3 and p38.";
RL   Oncogene 22:6129-6141(2003).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RA   Jenkins S.G., D'Andrea R.J., Gamble J.R., Vadas M.A.;
RT   "Characterization of human TAO1.";
RL   Submitted (JUL-2001) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RA   Matsuda A., Yoneta S.;
RT   "T cell activating gene.";
RL   Patent number WO2004058805, 15-JUL-2004.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Brain;
RX   PubMed=10718198; DOI=10.1093/dnares/7.1.65;
RA   Nagase T., Kikuno R., Ishikawa K., Hirosawa M., Ohara O.;
RT   "Prediction of the coding sequences of unidentified human genes. XVI. The
RT   complete sequences of 150 new cDNA clones from brain which code for large
RT   proteins in vitro.";
RL   DNA Res. 7:65-73(2000).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Placenta;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16625196; DOI=10.1038/nature04689;
RA   Zody M.C., Garber M., Adams D.J., Sharpe T., Harrow J., Lupski J.R.,
RA   Nicholson C., Searle S.M., Wilming L., Young S.K., Abouelleil A.,
RA   Allen N.R., Bi W., Bloom T., Borowsky M.L., Bugalter B.E., Butler J.,
RA   Chang J.L., Chen C.-K., Cook A., Corum B., Cuomo C.A., de Jong P.J.,
RA   DeCaprio D., Dewar K., FitzGerald M., Gilbert J., Gibson R., Gnerre S.,
RA   Goldstein S., Grafham D.V., Grocock R., Hafez N., Hagopian D.S., Hart E.,
RA   Norman C.H., Humphray S., Jaffe D.B., Jones M., Kamal M., Khodiyar V.K.,
RA   LaButti K., Laird G., Lehoczky J., Liu X., Lokyitsang T., Loveland J.,
RA   Lui A., Macdonald P., Major J.E., Matthews L., Mauceli E., McCarroll S.A.,
RA   Mihalev A.H., Mudge J., Nguyen C., Nicol R., O'Leary S.B., Osoegawa K.,
RA   Schwartz D.C., Shaw-Smith C., Stankiewicz P., Steward C., Swarbreck D.,
RA   Venkataraman V., Whittaker C.A., Yang X., Zimmer A.R., Bradley A.,
RA   Hubbard T., Birren B.W., Rogers J., Lander E.S., Nusbaum C.;
RT   "DNA sequence of human chromosome 17 and analysis of rearrangement in the
RT   human lineage.";
RL   Nature 440:1045-1049(2006).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 3).
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [9]
RP   TISSUE SPECIFICITY.
RX   PubMed=9786855; DOI=10.1074/jbc.273.44.28625;
RA   Hutchison M., Berman K.S., Cobb M.H.;
RT   "Isolation of TAO1, a protein kinase that activates MEKs in stress-
RT   activated protein kinase cascades.";
RL   J. Biol. Chem. 273:28625-28632(1998).
RN   [10]
RP   FUNCTION.
RX   PubMed=12665513; DOI=10.1074/jbc.m301173200;
RA   Chen Z., Raman M., Chen L., Lee S.F., Gilman A.G., Cobb M.H.;
RT   "TAO (thousand-and-one amino acid) protein kinases mediate signaling from
RT   carbachol to p38 mitogen-activated protein kinase and ternary complex
RT   factors.";
RL   J. Biol. Chem. 278:22278-22283(2003).
RN   [11]
RP   FUNCTION, PROTEOLYTIC PROCESSING, AND MUTAGENESIS OF LYS-57 AND ASP-376.
RX   PubMed=16407310; DOI=10.1074/jbc.m513769200;
RA   Zihni C., Mitsopoulos C., Tavares I.A., Ridley A.J., Morris J.D.;
RT   "Prostate-derived sterile 20-like kinase 2 (PSK2) regulates apoptotic
RT   morphology via C-Jun N-terminal kinase and Rho kinase-1.";
RL   J. Biol. Chem. 281:7317-7323(2006).
RN   [12]
RP   INTERACTION WITH MAP3K7.
RX   PubMed=16893890; DOI=10.1074/jbc.m603627200;
RA   Huangfu W.C., Omori E., Akira S., Matsumoto K., Ninomiya-Tsuji J.;
RT   "Osmotic stress activates the TAK1-JNK pathway while blocking TAK1-mediated
RT   NF-kappaB activation: TAO2 regulates TAK1 pathways.";
RL   J. Biol. Chem. 281:28802-28810(2006).
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-421, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=16964243; DOI=10.1038/nbt1240;
RA   Beausoleil S.A., Villen J., Gerber S.A., Rush J., Gygi S.P.;
RT   "A probability-based approach for high-throughput protein phosphorylation
RT   analysis and site localization.";
RL   Nat. Biotechnol. 24:1285-1292(2006).
RN   [14]
RP   FUNCTION, PHOSPHORYLATION BY ATM, INDUCTION, AND MUTAGENESIS OF ASP-169;
RP   THR-643; THR-785 AND SER-990.
RX   PubMed=17396146; DOI=10.1038/sj.emboj.7601668;
RA   Raman M., Earnest S., Zhang K., Zhao Y., Cobb M.H.;
RT   "TAO kinases mediate activation of p38 in response to DNA damage.";
RL   EMBO J. 26:2005-2014(2007).
RN   [15]
RP   POSSIBLE ROLE IN SPINDLE CHECKPOINT.
RX   PubMed=17417629; DOI=10.1038/ncb1569;
RA   Draviam V.M., Stegmeier F., Nalepa G., Sowa M.E., Chen J., Liang A.,
RA   Hannon G.J., Sorger P.K., Harper J.W., Elledge S.J.;
RT   "A functional genomic screen identifies a role for TAO1 kinase in spindle-
RT   checkpoint signalling.";
RL   Nat. Cell Biol. 9:556-564(2007).
RN   [16]
RP   FUNCTION.
RX   PubMed=17900936; DOI=10.1016/j.cellbi.2007.08.006;
RA   Wu M.F., Wang S.G.;
RT   "Human TAO kinase 1 induces apoptosis in SH-SY5Y cells.";
RL   Cell Biol. Int. 32:151-156(2008).
RN   [17]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-421 AND SER-965, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Platelet;
RX   PubMed=18088087; DOI=10.1021/pr0704130;
RA   Zahedi R.P., Lewandrowski U., Wiesner J., Wortelkamp S., Moebius J.,
RA   Schuetz C., Walter U., Gambaryan S., Sickmann A.;
RT   "Phosphoproteome of resting human platelets.";
RL   J. Proteome Res. 7:526-534(2008).
RN   [18]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-421, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of the
RT   kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [19]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-421 AND SER-445, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [20]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in a
RT   refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [21]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-9; SER-421 AND THR-669, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [22]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-9 AND SER-421, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [23]
RP   LACK OF ROLE IN SPINDLE CHECKPOINT.
RX   PubMed=19904549; DOI=10.1007/s00412-009-0244-2;
RA   Hubner N.C., Wang L.H., Kaulich M., Descombes P., Poser I., Nigg E.A.;
RT   "Re-examination of siRNA specificity questions role of PICH and Tao1 in the
RT   spindle checkpoint and identifies Mad2 as a sensitive target for small
RT   RNAs.";
RL   Chromosoma 119:149-165(2010).
RN   [24]
RP   LACK OF ROLE IN SPINDLE CHECKPOINT.
RX   PubMed=20162290; DOI=10.1007/s00412-010-0261-1;
RA   Westhorpe F.G., Diez M.A., Gurden M.D., Tighe A., Taylor S.S.;
RT   "Re-evaluating the role of Tao1 in the spindle checkpoint.";
RL   Chromosoma 119:371-379(2010).
RN   [25]
RP   PHOSPHORYLATION BY LRRK2.
RX   PubMed=20949042; DOI=10.1371/journal.pone.0013191;
RA   Zach S., Felk S., Gillardon F.;
RT   "Signal transduction protein array analysis links LRRK2 to Ste20 kinases
RT   and PKC zeta that modulate neuronal plasticity.";
RL   PLoS ONE 5:E13191-E13191(2010).
RN   [26]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [27]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-421, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T.,
RA   Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.;
RT   "System-wide temporal characterization of the proteome and phosphoproteome
RT   of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [28]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-9; SER-421; SER-445 AND
RP   SER-965, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [29]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [30]
RP   VARIANT [LARGE SCALE ANALYSIS] THR-855.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G.,
RA   Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S.,
RA   Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G.,
RA   Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K.,
RA   Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D.,
RA   Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R.,
RA   Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F.,
RA   Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F.,
RA   Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G.,
RA   Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R.,
RA   Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
RN   [31]
RP   VARIANTS DDIB GLY-17; PHE-111; GLU-298; ALA-305; 544-GLN--THR-1001 DEL;
RP   781-GLU--THR-1001 DEL AND 830-GLU--THR-1001 DEL, AND INVOLVEMENT IN DDIB.
RX   PubMed=31230721; DOI=10.1016/j.ajhg.2019.05.005;
RA   Dulovic-Mahlow M., Trinh J., Kandaswamy K.K., Braathen G.J., Di Donato N.,
RA   Rahikkala E., Beblo S., Werber M., Krajka V., Busk O.L., Baumann H.,
RA   Al-Sannaa N.A., Hinrichs F., Affan R., Navot N., Al Balwi M.A., Oprea G.,
RA   Holla O.L., Weiss M.E.R., Jamra R.A., Kahlert A.K., Kishore S., Tveten K.,
RA   Vos M., Rolfs A., Lohmann K.;
RT   "De Novo Variants in TAOK1 Cause Neurodevelopmental Disorders.";
RL   Am. J. Hum. Genet. 105:213-220(2019).
RN   [32]
RP   VARIANTS DDIB ILE-150; ARG-167; 220-GLU--THR-1001 DEL; VAL-231; PHE-315;
RP   PRO-548; 605-ARG--THR-1001 DEL; 607-GLN--THR-1001 DEL; 695-ARG--THR-1001
RP   DEL; 702-ARG--THR-1001 DEL AND 709-ARG--THR-1001 DEL, FUNCTION, AND
RP   CHARACTERIZATION OF VARIANTS DDIB ARG-167 AND PRO-548.
RX   PubMed=33565190; DOI=10.1002/humu.24176;
RA   van Woerden G.M., Bos M., de Konink C., Distel B., Avagliano Trezza R.,
RA   Shur N.E., Baranano K., Mahida S., Chassevent A., Schreiber A., Erwin A.L.,
RA   Gripp K.W., Rehman F., Brulleman S., McCormack R., de Geus G., Kalsner L.,
RA   Sorlin A., Bruel A.L., Koolen D.A., Gabriel M.K., Rossi M.,
RA   Fitzpatrick D.R., Wilkie A.O.M., Calpena E., Johnson D., Brooks A.,
RA   van Slegtenhorst M., Fleischer J., Groepper D., Lindstrom K., Innes A.M.,
RA   Goodwin A., Humberson J., Noyes A., Langley K.G., Telegrafi A., Blevins A.,
RA   Hoffman J., Guillen Sacoto M.J., Juusola J., Monaghan K.G., Punj S.,
RA   Simon M., Pfundt R., Elgersma Y., Kleefstra T.;
RT   "TAOK1 is associated with neurodevelopmental disorder and essential for
RT   neuronal maturation and cortical development.";
RL   Hum. Mutat. 42:445-459(2021).
CC   -!- FUNCTION: Serine/threonine-protein kinase involved in various processes
CC       such as p38/MAPK14 stress-activated MAPK cascade, DNA damage response
CC       and regulation of cytoskeleton stability. Phosphorylates MAP2K3, MAP2K6
CC       and MARK2. Acts as an activator of the p38/MAPK14 stress-activated MAPK
CC       cascade by mediating phosphorylation and subsequent activation of the
CC       upstream MAP2K3 and MAP2K6 kinases. Involved in G-protein coupled
CC       receptor signaling to p38/MAPK14. In response to DNA damage, involved
CC       in the G2/M transition DNA damage checkpoint by activating the
CC       p38/MAPK14 stress-activated MAPK cascade, probably by mediating
CC       phosphorylation of MAP2K3 and MAP2K6. Acts as a regulator of
CC       cytoskeleton stability by phosphorylating 'Thr-208' of MARK2, leading
CC       to activate MARK2 kinase activity and subsequent phosphorylation and
CC       detachment of MAPT/TAU from microtubules. Also acts as a regulator of
CC       apoptosis: regulates apoptotic morphological changes, including cell
CC       contraction, membrane blebbing and apoptotic bodies formation via
CC       activation of the MAPK8/JNK cascade. Plays an essential role in the
CC       regulation of neuronal development in the central nervous system
CC       (PubMed:33565190). Also plays a role in the regulation of neuronal
CC       migration to the cortical plate (By similarity).
CC       {ECO:0000250|UniProtKB:Q5F2E8, ECO:0000269|PubMed:12665513,
CC       ECO:0000269|PubMed:13679851, ECO:0000269|PubMed:16407310,
CC       ECO:0000269|PubMed:17396146, ECO:0000269|PubMed:17900936,
CC       ECO:0000269|PubMed:33565190}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-seryl-[protein] = ADP + H(+) + O-phospho-L-seryl-
CC         [protein]; Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA-
CC         COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1;
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-threonyl-[protein] = ADP + H(+) + O-phospho-L-
CC         threonyl-[protein]; Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060,
CC         Rhea:RHEA-COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:61977, ChEBI:CHEBI:456216;
CC         EC=2.7.11.1;
CC   -!- ACTIVITY REGULATION: Serine/threonine-protein kinase activity is
CC       inhibited by SPRED1.
CC   -!- SUBUNIT: Self-associates. Interacts with MAP2K3 (By similarity).
CC       Interacts with SPRED1 (By similarity). Interacts with TESK1; the
CC       interaction inhibits TAOK1 kinase activity (By similarity). Interacts
CC       with MAP3K7. {ECO:0000250, ECO:0000250|UniProtKB:O88664,
CC       ECO:0000269|PubMed:16893890}.
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:13679851}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=Q7L7X3-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q7L7X3-2; Sequence=VSP_015964, VSP_015965, VSP_015966;
CC       Name=3;
CC         IsoId=Q7L7X3-3; Sequence=VSP_043706;
CC   -!- TISSUE SPECIFICITY: Highly expressed in the testis, and to a lower
CC       extent also expressed in brain, placenta, colon and skeletal muscle.
CC       {ECO:0000269|PubMed:13679851, ECO:0000269|PubMed:9786855}.
CC   -!- INDUCTION: In response to DNA damage. {ECO:0000269|PubMed:17396146}.
CC   -!- PTM: Proteolytically processed by caspase-3 (CASP3).
CC       {ECO:0000269|PubMed:16407310}.
CC   -!- PTM: Autophosphorylated (By similarity). Phosphorylated by ATM in
CC       response to DNA damage. Phosphorylated by LRRK2. {ECO:0000250,
CC       ECO:0000269|PubMed:17396146, ECO:0000269|PubMed:20949042}.
CC   -!- DISEASE: Developmental delay with or without intellectual impairment or
CC       behavioral abnormalities (DDIB) [MIM:619575]: An autosomal dominant
CC       disorder characterized by a highly variable phenotype of developmental
CC       delay, intellectual disability, learning or behavioral problems,
CC       muscular hypotonia, and neonatal feeding difficulties.
CC       {ECO:0000269|PubMed:31230721, ECO:0000269|PubMed:33565190}. Note=The
CC       disease is caused by variants affecting the gene represented in this
CC       entry.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thr
CC       protein kinase family. STE20 subfamily. {ECO:0000305}.
CC   -!- CAUTION: Was initially thought to play a role in the spindle checkpoint
CC       (PubMed:17417629). However, it was later shown that it is not the case
CC       and that phenotypes initially observed are the cause of the siRNA used
CC       that has an off-target effect resulting in MAD2L1 inhibition
CC       (PubMed:19904549 and PubMed:20162290). {ECO:0000305|PubMed:17417629}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAA92599.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF263312; AAG38502.1; -; mRNA.
DR   EMBL; AY049015; AAL12217.1; -; mRNA.
DR   EMBL; CQ834802; CAH05616.1; -; mRNA.
DR   EMBL; AB037782; BAA92599.1; ALT_INIT; mRNA.
DR   EMBL; AK024376; BAB14901.1; -; mRNA.
DR   EMBL; AC068025; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC068588; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC090698; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471159; EAW51188.1; -; Genomic_DNA.
DR   EMBL; BC133039; AAI33040.1; -; mRNA.
DR   EMBL; BC144067; AAI44068.1; -; mRNA.
DR   CCDS; CCDS32601.1; -. [Q7L7X3-1]
DR   CCDS; CCDS56024.1; -. [Q7L7X3-3]
DR   RefSeq; NP_065842.1; NM_020791.2. [Q7L7X3-1]
DR   RefSeq; NP_079418.1; NM_025142.1. [Q7L7X3-3]
DR   RefSeq; XP_011523362.1; XM_011525060.2.
DR   AlphaFoldDB; Q7L7X3; -.
DR   SMR; Q7L7X3; -.
DR   BioGRID; 121607; 35.
DR   DIP; DIP-39709N; -.
DR   IntAct; Q7L7X3; 24.
DR   MINT; Q7L7X3; -.
DR   STRING; 9606.ENSP00000261716; -.
DR   BindingDB; Q7L7X3; -.
DR   ChEMBL; CHEMBL5261; -.
DR   DrugBank; DB12010; Fostamatinib.
DR   DrugCentral; Q7L7X3; -.
DR   GuidetoPHARMACOLOGY; 2233; -.
DR   GlyGen; Q7L7X3; 1 site, 1 O-linked glycan (1 site).
DR   iPTMnet; Q7L7X3; -.
DR   MetOSite; Q7L7X3; -.
DR   PhosphoSitePlus; Q7L7X3; -.
DR   BioMuta; TAOK1; -.
DR   DMDM; 74759012; -.
DR   EPD; Q7L7X3; -.
DR   jPOST; Q7L7X3; -.
DR   MassIVE; Q7L7X3; -.
DR   MaxQB; Q7L7X3; -.
DR   PaxDb; Q7L7X3; -.
DR   PeptideAtlas; Q7L7X3; -.
DR   PRIDE; Q7L7X3; -.
DR   ProteomicsDB; 68829; -. [Q7L7X3-1]
DR   ProteomicsDB; 68830; -. [Q7L7X3-2]
DR   ProteomicsDB; 68831; -. [Q7L7X3-3]
DR   Antibodypedia; 2089; 390 antibodies from 31 providers.
DR   DNASU; 57551; -.
DR   Ensembl; ENST00000261716.8; ENSP00000261716.3; ENSG00000160551.12. [Q7L7X3-1]
DR   Ensembl; ENST00000536202.1; ENSP00000438819.1; ENSG00000160551.12. [Q7L7X3-3]
DR   GeneID; 57551; -.
DR   KEGG; hsa:57551; -.
DR   MANE-Select; ENST00000261716.8; ENSP00000261716.3; NM_020791.4; NP_065842.1.
DR   UCSC; uc002hdz.3; human. [Q7L7X3-1]
DR   CTD; 57551; -.
DR   DisGeNET; 57551; -.
DR   GeneCards; TAOK1; -.
DR   HGNC; HGNC:29259; TAOK1.
DR   HPA; ENSG00000160551; Low tissue specificity.
DR   MalaCards; TAOK1; -.
DR   MIM; 610266; gene.
DR   MIM; 619575; phenotype.
DR   neXtProt; NX_Q7L7X3; -.
DR   OpenTargets; ENSG00000160551; -.
DR   Orphanet; 178469; Autosomal dominant non-syndromic intellectual disability.
DR   PharmGKB; PA134872946; -.
DR   VEuPathDB; HostDB:ENSG00000160551; -.
DR   eggNOG; KOG0577; Eukaryota.
DR   GeneTree; ENSGT00940000155796; -.
DR   HOGENOM; CLU_000288_2_2_1; -.
DR   InParanoid; Q7L7X3; -.
DR   OMA; XAKVMAN; -.
DR   PhylomeDB; Q7L7X3; -.
DR   TreeFam; TF351444; -.
DR   PathwayCommons; Q7L7X3; -.
DR   Reactome; R-HSA-141444; Amplification of signal from unattached kinetochores via a MAD2 inhibitory signal.
DR   Reactome; R-HSA-2467813; Separation of Sister Chromatids.
DR   Reactome; R-HSA-2500257; Resolution of Sister Chromatid Cohesion.
DR   Reactome; R-HSA-5663220; RHO GTPases Activate Formins.
DR   Reactome; R-HSA-68877; Mitotic Prometaphase.
DR   Reactome; R-HSA-9648025; EML4 and NUDC in mitotic spindle formation.
DR   SignaLink; Q7L7X3; -.
DR   SIGNOR; Q7L7X3; -.
DR   BioGRID-ORCS; 57551; 55 hits in 1127 CRISPR screens.
DR   ChiTaRS; TAOK1; human.
DR   GeneWiki; TAOK1; -.
DR   GenomeRNAi; 57551; -.
DR   Pharos; Q7L7X3; Tchem.
DR   PRO; PR:Q7L7X3; -.
DR   Proteomes; UP000005640; Chromosome 17.
DR   RNAct; Q7L7X3; protein.
DR   Bgee; ENSG00000160551; Expressed in corpus callosum and 196 other tissues.
DR   ExpressionAtlas; Q7L7X3; baseline and differential.
DR   Genevisible; Q7L7X3; HS.
DR   GO; GO:0005737; C:cytoplasm; IBA:GO_Central.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB.
DR   GO; GO:0015630; C:microtubule cytoskeleton; IMP:ARUK-UCL.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; IMP:ARUK-UCL.
DR   GO; GO:0043014; F:alpha-tubulin binding; IDA:ARUK-UCL.
DR   GO; GO:0005524; F:ATP binding; NAS:HGNC-UCL.
DR   GO; GO:0048487; F:beta-tubulin binding; IDA:ARUK-UCL.
DR   GO; GO:0016301; F:kinase activity; IDA:ARUK-UCL.
DR   GO; GO:0004672; F:protein kinase activity; ISS:ARUK-UCL.
DR   GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA.
DR   GO; GO:0043539; F:protein serine/threonine kinase activator activity; ISS:ARUK-UCL.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; ISS:UniProtKB.
DR   GO; GO:0048156; F:tau protein binding; NAS:ARUK-UCL.
DR   GO; GO:0050321; F:tau-protein kinase activity; NAS:ARUK-UCL.
DR   GO; GO:0016740; F:transferase activity; NAS:HGNC-UCL.
DR   GO; GO:0006974; P:cellular response to DNA damage stimulus; IDA:UniProtKB.
DR   GO; GO:0021954; P:central nervous system neuron development; IMP:UniProtKB.
DR   GO; GO:0006281; P:DNA repair; IEA:UniProtKB-KW.
DR   GO; GO:0097194; P:execution phase of apoptosis; IDA:UniProtKB.
DR   GO; GO:0035556; P:intracellular signal transduction; IBA:GO_Central.
DR   GO; GO:0000165; P:MAPK cascade; IBA:GO_Central.
DR   GO; GO:0000226; P:microtubule cytoskeleton organization; IMP:ARUK-UCL.
DR   GO; GO:0007095; P:mitotic G2 DNA damage checkpoint signaling; IMP:UniProtKB.
DR   GO; GO:0007026; P:negative regulation of microtubule depolymerization; IMP:ARUK-UCL.
DR   GO; GO:0070050; P:neuron cellular homeostasis; IMP:ARUK-UCL.
DR   GO; GO:0048812; P:neuron projection morphogenesis; IBA:GO_Central.
DR   GO; GO:0016310; P:phosphorylation; IDA:ARUK-UCL.
DR   GO; GO:0046330; P:positive regulation of JNK cascade; IDA:UniProtKB.
DR   GO; GO:1901985; P:positive regulation of protein acetylation; IMP:ARUK-UCL.
DR   GO; GO:0032874; P:positive regulation of stress-activated MAPK cascade; IMP:UniProtKB.
DR   GO; GO:0046777; P:protein autophosphorylation; ISS:ARUK-UCL.
DR   GO; GO:0006468; P:protein phosphorylation; IBA:GO_Central.
DR   GO; GO:0032956; P:regulation of actin cytoskeleton organization; ISS:ARUK-UCL.
DR   GO; GO:0051493; P:regulation of cytoskeleton organization; ISS:UniProtKB.
DR   GO; GO:0043408; P:regulation of MAPK cascade; IBA:GO_Central.
DR   GO; GO:0070507; P:regulation of microtubule cytoskeleton organization; ISS:ARUK-UCL.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   Pfam; PF00069; Pkinase; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; Apoptosis; ATP-binding; Coiled coil; Cytoplasm;
KW   Disease variant; DNA damage; DNA repair; Intellectual disability; Kinase;
KW   Nucleotide-binding; Phosphoprotein; Reference proteome;
KW   Serine/threonine-protein kinase; Transferase.
FT   CHAIN           1..1001
FT                   /note="Serine/threonine-protein kinase TAO1"
FT                   /id="PRO_0000086728"
FT   DOMAIN          28..281
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   REGION          324..433
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          567..587
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          911..1001
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COILED          458..651
FT                   /evidence="ECO:0000255"
FT   COILED          754..877
FT                   /evidence="ECO:0000255"
FT   COMPBIAS        340..374
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        400..415
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        958..1001
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   ACT_SITE        151
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159,
FT                   ECO:0000255|PROSITE-ProRule:PRU10027"
FT   BINDING         34..42
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   BINDING         57
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000305"
FT   MOD_RES         9
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:19369195,
FT                   ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:23186163"
FT   MOD_RES         421
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:16964243,
FT                   ECO:0007744|PubMed:18088087, ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:18691976, ECO:0007744|PubMed:19369195,
FT                   ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:21406692,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         445
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         669
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:19369195"
FT   MOD_RES         965
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18088087,
FT                   ECO:0007744|PubMed:23186163"
FT   VAR_SEQ         1..174
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_015964"
FT   VAR_SEQ         569..716
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_043706"
FT   VAR_SEQ         569..572
FT                   /note="ELNE -> VLMS (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_015965"
FT   VAR_SEQ         573..1001
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_015966"
FT   VARIANT         17
FT                   /note="E -> G (in DDIB)"
FT                   /evidence="ECO:0000269|PubMed:31230721"
FT                   /id="VAR_086415"
FT   VARIANT         111
FT                   /note="S -> F (in DDIB)"
FT                   /evidence="ECO:0000269|PubMed:31230721"
FT                   /id="VAR_086416"
FT   VARIANT         150
FT                   /note="R -> I (in DDIB)"
FT                   /evidence="ECO:0000269|PubMed:33565190"
FT                   /id="VAR_086417"
FT   VARIANT         167
FT                   /note="L -> R (in DDIB; affects neuron maturation and
FT                   migration)"
FT                   /evidence="ECO:0000269|PubMed:33565190"
FT                   /id="VAR_086418"
FT   VARIANT         220..1001
FT                   /note="Missing (in DDIB)"
FT                   /evidence="ECO:0000269|PubMed:33565190"
FT                   /id="VAR_086419"
FT   VARIANT         231
FT                   /note="M -> V (in DDIB; unknown pathological significance)"
FT                   /evidence="ECO:0000269|PubMed:33565190"
FT                   /id="VAR_086420"
FT   VARIANT         298
FT                   /note="K -> E (in DDIB)"
FT                   /evidence="ECO:0000269|PubMed:31230721"
FT                   /id="VAR_086421"
FT   VARIANT         305
FT                   /note="D -> A (in DDIB)"
FT                   /evidence="ECO:0000269|PubMed:31230721"
FT                   /id="VAR_086422"
FT   VARIANT         315
FT                   /note="L -> F (in DDIB; unknown pathological significance)"
FT                   /evidence="ECO:0000269|PubMed:33565190"
FT                   /id="VAR_086423"
FT   VARIANT         544..1001
FT                   /note="Missing (in DDIB)"
FT                   /evidence="ECO:0000269|PubMed:31230721"
FT                   /id="VAR_086424"
FT   VARIANT         548
FT                   /note="L -> P (in DDIB; affects neuron maturation and
FT                   migration)"
FT                   /evidence="ECO:0000269|PubMed:33565190"
FT                   /id="VAR_086425"
FT   VARIANT         605..1001
FT                   /note="Missing (in DDIB)"
FT                   /evidence="ECO:0000269|PubMed:33565190"
FT                   /id="VAR_086426"
FT   VARIANT         607..1001
FT                   /note="Missing (in DDIB)"
FT                   /evidence="ECO:0000269|PubMed:33565190"
FT                   /id="VAR_086427"
FT   VARIANT         695..1001
FT                   /note="Missing (in DDIB)"
FT                   /evidence="ECO:0000269|PubMed:33565190"
FT                   /id="VAR_086428"
FT   VARIANT         702..1001
FT                   /note="Missing (in DDIB)"
FT                   /evidence="ECO:0000269|PubMed:33565190"
FT                   /id="VAR_086429"
FT   VARIANT         709..1001
FT                   /note="Missing (in DDIB)"
FT                   /evidence="ECO:0000269|PubMed:33565190"
FT                   /id="VAR_086430"
FT   VARIANT         781..1001
FT                   /note="Missing (in DDIB)"
FT                   /evidence="ECO:0000269|PubMed:31230721"
FT                   /id="VAR_086431"
FT   VARIANT         830..1001
FT                   /note="Missing (in DDIB)"
FT                   /evidence="ECO:0000269|PubMed:31230721"
FT                   /id="VAR_086432"
FT   VARIANT         855
FT                   /note="A -> T (in dbSNP:rs34151057)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041204"
FT   MUTAGEN         57
FT                   /note="K->A: Abolishes kinase activity, ability to activate
FT                   the MAPK8/JNK cascade and cleavage by caspase-3 (CASP3)."
FT                   /evidence="ECO:0000269|PubMed:16407310"
FT   MUTAGEN         169
FT                   /note="D->A: Loss of serine/threonine-protein kinase
FT                   activity."
FT                   /evidence="ECO:0000269|PubMed:17396146"
FT   MUTAGEN         376
FT                   /note="D->N: Does not abolish cleavage by caspase-3
FT                   (CASP3)."
FT                   /evidence="ECO:0000269|PubMed:16407310"
FT   MUTAGEN         643
FT                   /note="T->A: Abolishes phosphorylation by ATM; when
FT                   associated with A-785 and A-990."
FT                   /evidence="ECO:0000269|PubMed:17396146"
FT   MUTAGEN         785
FT                   /note="T->A: Abolishes phosphorylation by ATM; when
FT                   associated with A-643 and A-990."
FT                   /evidence="ECO:0000269|PubMed:17396146"
FT   MUTAGEN         990
FT                   /note="S->A: Abolishes phosphorylation by ATM; when
FT                   associated with A-643 and A-785."
FT                   /evidence="ECO:0000269|PubMed:17396146"
FT   CONFLICT        251
FT                   /note="S -> T (in Ref. 5; BAB14901)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        257
FT                   /note="F -> S (in Ref. 1; AAG38502)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        860
FT                   /note="R -> C (in Ref. 1; AAG38502)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   1001 AA;  116070 MW;  82941DEAEADC7651 CRC64;
     MPSTNRAGSL KDPEIAELFF KEDPEKLFTD LREIGHGSFG AVYFARDVRT NEVVAIKKMS
     YSGKQSTEKW QDIIKEVKFL QRIKHPNSIE YKGCYLREHT AWLVMEYCLG SASDLLEVHK
     KPLQEVEIAA ITHGALQGLA YLHSHTMIHR DIKAGNILLT EPGQVKLADF GSASMASPAN
     SFVGTPYWMA PEVILAMDEG QYDGKVDVWS LGITCIELAE RKPPLFNMNA MSALYHIAQN
     ESPTLQSNEW SDYFRNFVDS CLQKIPQDRP TSEELLKHIF VLRERPETVL IDLIQRTKDA
     VRELDNLQYR KMKKLLFQEA HNGPAVEAQE EEEEQDHGVG RTGTVNSVGS NQSIPSMSIS
     ASSQSSSVNS LPDVSDDKSE LDMMEGDHTV MSNSSVIHLK PEEENYREEG DPRTRASDPQ
     SPPQVSRHKS HYRNREHFAT IRTASLVTRQ MQEHEQDSEL REQMSGYKRM RRQHQKQLMT
     LENKLKAEMD EHRLRLDKDL ETQRNNFAAE MEKLIKKHQA AMEKEAKVMS NEEKKFQQHI
     QAQQKKELNS FLESQKREYK LRKEQLKEEL NENQSTPKKE KQEWLSKQKE NIQHFQAEEE
     ANLLRRQRQY LELECRRFKR RMLLGRHNLE QDLVREELNK RQTQKDLEHA MLLRQHESMQ
     ELEFRHLNTI QKMRCELIRL QHQTELTNQL EYNKRREREL RRKHVMEVRQ QPKSLKSKEL
     QIKKQFQDTC KIQTRQYKAL RNHLLETTPK SEHKAVLKRL KEEQTRKLAI LAEQYDHSIN
     EMLSTQALRL DEAQEAECQV LKMQLQQELE LLNAYQSKIK MQAEAQHDRE LRELEQRVSL
     RRALLEQKIE EEMLALQNER TERIRSLLER QAREIEAFDS ESMRLGFSNM VLSNLSPEAF
     SHSYPGASGW SHNPTGGPGP HWGHPMGGPP QAWGHPMQGG PQPWGHPSGP MQGVPRGSSM
     GVRNSPQALR RTASGGRTEQ GMSRSTSVTS QISNGSHMSY T
//
